Login to Your Account

Myogen's Enoximone Falters, Placebo Surprise' To Blame

By Randall Osborne

Monday, March 29, 2004
Myogen Inc.'s lead product, enoximone, missed statistical significance in the primary endpoint of a Phase III trial to support an ongoing pair of other, pivotal Phase III studies - but the company said success in secondary endpoints means the study's objective was achieved. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription